This enhanced cancer suppression was attributed to the ability of GCD–PEG–Tf@DOX to selectively target cancer cells and longer circulation time in vivo, highlighting its potential as a targeted drug delivery and cancer therapy. The gene discussed is TF; the disease is cancer.